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Abstract We report here the isolation from Drosophila mela- 
nogaster of a 2.0 kb cDNA clone encoding a 385 amino acid 
protein (dDA1) displaying, within putative transmembrane do- 
mains, highest amino acid sequence homology (49-53%) to mem- 
bers of the vertebrate dopamine Dl-like receptor family. When 
expressed in either Sf9 or COS-7 cells, dDA1 did not bind the 
specific Dl-like receptor antagonist [3H]SCH-23390 or numerous 
other dopaminergic, adrenergic or serotoninergic ligands with 
high affinity. However, like vertebrate dopamine Dl-like recep- 
tors, dDAI stimulated the accumulation of cAMP in response to 
DA (EC5o ~300 riM) and 6,7-ADTN (ECs0 -500 nM). The dopa- 
minergic rank order of potency (DA > NE >> 5-HT) and the lack 
of stimulation by other possible neurotransmitters (octopamine, 
tyramine, tryptamine) or DA metabolites (e.g. N-acetyl dopa- 
mine) found in Drosophila suggests that this receptor functionally 
belongs to the dopamine Dl-like subfamily. Benzazepines, which 
characteristically bind to vertebrate dopamine Dl-like receptors 
with high affinity, were relatively poor in stimulating (SKF- 
38393, SKF-82526; ECho > 10 btM) dDAl-mediated accumula- 
tion of cAMP. Of the numerous compounds tested, a few dopa- 
minergic antagonists inhibited DA-stimulated production of 
cAMP in a concentration-dependent manner, albeit with consid- 
erably reduced affinity, and with the rank order of potency: (+)- 
butaclamol(Kb~125nM ) > SCH-23390(Kb~230nM) > a-flupen- 
thixol (K b -400 nM) > chlorpromazine --- spiperone (K b ~680 
nM) -> clozapine. In situ hybridization revealed that dDA1 recep- 
tor mRNA is expressed as a maternal transcript, and at later 
blastoderm stages is restricted to apical regions of the cortical 
peripheral cytoplasm. The generation of inter-species D1 recep- 
tor chimeras may help to identify those particular sequence-spe- 
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Abbreviations: (-+)-6,7-ADTN, 6 7-dihyroxy-2-aminotetralin; CY 208 
243, (-)-4,6,6a,7,8, 12b-hexahydro-7-methyl-indolo[4,3-ab]-phenan- 
thridine; DA, dopamine; DHA, dihydroalprenolol; 8-OH-DPAT, (+)- 
8-hydroxy-N, -dipropyl-2-aminotetralin; 5-HT, serotonin (5-hydroxy- 
tryptamine); L-dopa, L-3,4-dihydroxphenylalanine; LSD, lysergic acid 
diethylamine; NE, norepinephrine; N(-)-NPA, N-propyl-norapomor- 
phine; SCH-23390, (R)-(+)-7-chloro-8-hydroxy-3-methyl-l-phenyl- 
2,3,4,5-tetrahydro-lH-3-benzazepine; SKF-38393, 2,3,4,5-tetrahydro- 
7,8-dihydroxy-l-phenyl-lH-3-benzazepine; SKF-81927, 6-chloro-7,8- 
dihydroxy- 1-phenyl-2,3,4,5-tetrahydro- 1H-3-benzazepine; SKF-82526, 
6-chloro-7,8-dihydroxy- 1 -(p hydroxyphenyl)-2,3,4,5-tetrahydro-(1H)- 
3-benzazepine; TM, transmembrane; WB-4101, 2-(2,6-dimethoxyphen- 
oxyethyl)aminomethyl-l,4-benzodioxane; YM-09151-2, eis-N-(1-ben- 
zyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylamino-benz- 
amide. 
cific motifs or amino acid residues confering high affinity benzaz- 
epine receptor interactions. 
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1. Introduction 
Dopamine, a neurotransmitter in the nervous ystem of ver- 
tebrates, acts on a number of central and peripheral receptors 
to exert its physiological nd neuromodulator effects [1,2]. Re- 
ceptors for dopamine have been cloned and characterized from 
several vertebrate species. These receptors have typically been 
classified as Dl-like (D1, D1B/D5) or D2-1ike (D2, D3, D4) 
based on pharmacological, biochemical and structural criteria 
(for reviews see [3-5]). The recent cloning of the D1C receptor 
from Xenopus laevis [6] and D 1D receptor from Gallus domesti- 
cus [7] confirm that the the Dl-like receptor family is as heter- 
ogeneous and complex as pharmacological, behavioural nd/or 
biochemical data suggest [8-14]. 
Dopamine receptors are believed to exist in the invertebrate 
nervous ystem; however, the positive identification and classi- 
fication of such receptors is inconclusive based on the existing 
pharmacological nd biochemical data (for review see [15]). 
Dopamine is present in relative abundance in the invertebrate 
CNS, and dopamine-sensitive adenylyl cyclase has been ob- 
served in the molluscan and arthropod nervous ystem [16-19]. 
Biochemical, electrophysiological and behavioural studies indi- 
cate that putative invertebrate dopamine receptors possess 
pharmacological profiles distinct from mammalian or verte- 
brate dopamine receptors [15]. 
Whereas receptors for serotonin and tyramine have been 
cloned and functionally expressed from Drosophila [20-23], 
dopamine D1- or D2-1ike receptor genes have not yet been 
functionally characterized from this species. Dopaminergic 
neurons and pathways have, in particular, been well mapped 
by glyoxylic acid-induced histofluorescence and immunohisto- 
chemistry in the CNS of Drosophila melanogaster [24,25]. A role 
for dopamine as a neurotransmitter has not been clearly de- 
fined in Drosophila CNS; however, alterations in the synthesis 
of dopamine and/or serotonin by mutants genetically deficient 
in dopa decarboxylase (DDC) appear to result in pertubations 
of learning [26]. Several well-characterized genetic mutations 
prominently expressed in the mushroom bodies affect learning 
and memory, such as dunce (a cAMP phosphodiesterase), 
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rutabaga (a Ca2+/calmodulin-sensitive ad nylyl cyclase), and 
DCO (protein kinase A catalytic subunit) [27]. Interestingly, 
dopaminergic fibers have been found to innervate the mush- 
room bodies of Drosophila [25]. Because Drosophila is such an 
ideal model for genetic manipulations, and since little is known 
about the pharmacology, structure and functional coupling of 
dopamine receptors, we initiated a program to isolate dopamin- 
ergic D l-like receptors from Drosophila. 
We report here the cloning of a Drosophila melanogaster 
dopamine Dl- l ike receptor, which, like its vertebrate counter- 
parts, potently stimulates adenylyl cyclase activity. This recep- 
tor, however, is pharmacologically distinct from vertebrate D1 
receptors, displaying poor affinity for benzazepine ligands. The 
cloning of a Dl- l ike receptor with low overall homology to 
vertebrate dopamine D l-like receptors may facilitate the identi- 
fication of the amino acid residues and/or structural motifs that 
are conserved throughout D1 receptor evolution and which 
may impart functional and pharmacological specificity. Fur- 
thermore, the presence of this receptor in the Drosophila CNS 
substantiates the view that dopamine may have been well estab- 
lished as a neurotransmitter before the separation of arthropod 
and chordate lineages [28]. 
2. Materials and methods 
2.1. Isolation of Drosophila genomic and cDNA clone 
A Drosophila melanogaster adult Canton S strain genomic library 
(Clontech) was screened with a 32p-labeled human dopamine D5 recep- 
tor fragment [29] corresponding toTM domains 2-5 under conditions 
previously described [6]. Approximately 105 independent clones were 
screened under the following conditions: duplicate nylon filters (NEN/ 
Dupont) were hybridized at 42°C in a solution [30] containing 32p_ 
labeled D5 fragment (2 × 10 6 cpm/ml). Filters were washed twice in 2 × 
SSC, 1% SDS for 15 min at 60°C. Upon plaque purification of hybridiz- 
ing clones, subcloning and Southern blot analysis, a 800 pb PstI frag- 
ment was identified by sequence analysis to contain regions showing 
homology to the first extracellular loop between TM2 and TM3 and 
the putative TM 3 region of the dopamine D5 receptor. Because an 
intron was present after TM3, a Pstl-ClaI 250 bp fragment was labeled 
with 32p and used to screen an adult head Drosophila cDNA library 
under conditions described above. Four positive clones (1.8 2.0 kb) 
were isolated and found by restriction mapping and sequencing to be 
identical to each other and to contain asequence identical to the partial 
genomic fragment. Following subcloning into pBluescript SK- (Strat- 
agene), both strands of one clone (dDA1) were sequenced using the 
Sanger dideoxy-chain termination method with 7-deaza-dGTP and Se- 
quenase (USB) with either specific internal primers (Biotechnology 
Service Centre HSC, Toronto) or T7/T3 primers. 
2.2. Cell culture and expression i  COS-7 cells 
COS-7 cells were grown on 150 mm plates in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal bovine serum at 37°C, 
5% CO2. The dDA1 cDNA clone was subcloned into the expression 
vector PCD-PS for transient expression [31]. COS-7 cells were trans- 
fected with the cesium-purified constructs by electroporation asprevi- 
ously described [30]. 
2.3. Cell culture and expression i  Sf9 cells 
The dDA1 cDNA was cloned in the transfer plasmid pBlueBacIII 
(Invitrogen). Log phase Sf9 (Sporodoptera f ugiperda) cells grown in 
complete Grace's insect media TNM-FH (Gibco BRL) at 27°C in a 
humid environment were seeded at a cell density of 2 x 10 6 per 60 mm 
plate. Cesium-purified pBlueBacllI-dDA1 was subsequently co-trans- 
fected with linearized wild-type AcMNPV DNA (Invitrogen) using the 
cationic liposome-mediated transfer essentially as described by the 
manufacturer. The recombinant virus was purified by several rounds 
of plaque purification to ensure no wild-type virus was present, and was 
tested by PCR analysis with internal oligonucleotide primers (5' oligo, 
5'-ATTTTGTGATACTTGGGTGGCCTT-3'; 3' oligo, 5'-AACTCC- 
TTGTTGAAGATCGAATAG-3'). 
2.4. cAMP accumulation 
COS-7 cells transiently expressing the dDA 1 clone and untransfected 
cells were tested for cAMP accumulation as described previously [6]. 
For testing stimulation of cAMP production in St9 cells grown in Sf900 
media (Gibco/BRL), the cells were first split into 24 well plates and 
infected with the dDA1 virus (2 x l0  6 pfu/well). After 48 h, the wells 
were washed once with prewarmed Graces' incomplete media contain- 
ing 0.5 mM 3-isobutyl-l-methylxanthine. Ceilswere incubated in 0.4 ml 
of the afore-mentioned medium in the presence or absence of the indi- 
cated concentration of antagonist for 15 min at 27°C followed by the 
addition of agonist for an additional 15 min at 27°C. Reactions were 
stopped by the addition of 500 pl of 0.2 N HCI, the cellular debris 
pelleted by centrifugation (500 x g) and supernatants (5-10/11) assayed 
for cAMP formation by radioimmunoassay (Amersham). 
2.5. In situ localization of dDA1 receptor mRNA 
Probes for in situ hybridization were generated by random priming 
to digoxygenin-dUTP of a 350 bp XbaI-EcoRI fragment representing 
primarily the 3' untranslated region of dDA1 cDNA. Collection and 
processing of embryos for in situ hybridization was essentially as de- 
scribed in Quan et al. [32]. 
3. Results and discussion 
Using a strategy based on homology probing with the 
dopamine D5 receptor we isolated a partial genomic dopamine 
D l-like receptor fragment, encoding the first intracellular loop, 
TM3 and part of the second extracellular loop from Drosophila 
melanogaster. Consensus sequences for 3' and 5' splice sites 
were present in this fragment before and after the small coding 
region [33]. Due to the presence of introns, a PstI-ClaI 250 bp 
coding fragment was used to screen a Drosophila adult head 
cDNA library. Four cDNA clones were isolated and found to 
be identical to each other. Sequence analysis of one of these 
clones indicated that it contained a putative inititiation 
methionine with predicted Kozak sequence [34] followed by a 
long open reading frame of 1155 nucleotides encoding a 385 
amino acid protein of calculated molecular mass of 43,139 Da. 
Hydrophobicity analysis of the deduced amino acid sequence 
(data not shown) revealed the presence of 7 hydrophobic amino 
acid segments that form putative transmembrane domains. 
Comparison of the deduced amino acid sequence of dDA 1 with 
other G protein-coupled receptors indicates that the regions of 
greatest homology occur within these putative transmembrane 
domains (Fig. 1). The degree of sequence identity within these 
TM domains was highest with the dopamine Dl- l ike receptor 
subfamily: 53% to Xenopus DIA  and D1C receptors; 52% to 
Xenopus D1B; 51% to human D1, chicken D1A and D ID  
Fig. 1. Deduced amino acid alignment of Drosophila dDA1 to cloned members of the dopamine Dl-like receptor family. Boxed and shaded areas 
denote absolutely conserved amino acid residues among all receptors presented. Boxed only regions indicate amino acid residues conserved between 
dDA 1 and at least wo other dopamine D l-like receptors. Putative transmembrane domains are demarcated above. Consensus sequences for potential 
protein kinase A (PKA) phosphorylation sites are indicated by filled squares. The single letter amino acid code is used. Sequences sources are as 
follows: human DI [31,53,54], monkey D1 [55], rat D1A [53], opposum D1A [56], goldfish D1 [57], Xen D1A, D1B and D1C [6], human D5 [29,58,59], 
rat D1B [60], chicken D1A, D1B, DID [7]. 
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receptors; and 49% to human D5 and chicken DIB receptors. 
dDA1 sequence identity within TM domains to other biogenic 
amine G-linked receptors i : 46% to the human dopamine D2L; 
45% to humanfll andfl3 ARs, Drosophila 5HTdrol and tyram- 
ine; 44% to human f12 AR and dopamine D4; 43% to human 
dopamine D3 and ctlA AR; and 41% to human ~2 AR. Overall 
amino acid sequence identities are considerably lower, dDA1 
displays 22% amino acid sequence identity with the 5HTdrol 
and tyramine receptors; 26% to human dopamine D2L and D3 
receptors; 27% to human ~IA and f12 AR; 28% to human ct2 
AR, fll AR, and dopamine D4 receptors and 30% to f13 AR. 
The dDA 1 receptor appears to display a slightly higher degree 
of overall sequence homology to vertebrate dopamine Dl-like 
receptors (29% to human dopamine D1, chicken D1A and DI B 
receptors, 30% to Xenopus dopamine D1A and D1C, 31% to 
human D5 and chicken D1D receptors, and 33% to Xenopus 
dopamine D1B receptor). 
Conserved in dDA1 are the aspartic residue (Asp 97) in TM3, 
two cysteine residues that may partake in disulfide bond forma- 
tion between the second and third extracellular loops [35], and 
two serine (SerlS9; Ser 192) residues in TM5 that may form part 
of the dopamine binding pocket [36]. No putative sites for 
N-linked glycosylation sites are apparent in the amino-terminus 
or second extracellular loop where almost all vertebrate 
dopamine DI receptors have one N-linked glycosylation site. 
One conserved putative protein kinase C site is found in the 
second cytoplasmic loop (T130) while several other non-con- 
served putative protein kinase C sites are found in the third 
cytoplasmic loop (S 217, S 235) and carboxy-tail (T 336, S 355, $372). 
Thus far, the presence of these putative phosphorylation sites 
within the carboxy-tail has been unique to only the Xenopus 
D1C and chicken DID receptors. The functional significance 
of these sites is at present unknown but may play a role in 
receptor desensitization. 
Other rather unique structural features of dDA1 include a 
very short extracellular loop between TM6 and TM7 and the 
relatively short carboxy-tail. Moreover, sequences in the third 
cytoplamic loop and intracellular carboxy-tail do not show 
strong sequence conservation with vertebrate Dl-like recep- 
tors. Minigene and mutagenesis studies indicate that the third 
cytoplasmic loop is important for mediating receptor coupling 
to subtype-specific G proteins [3740]. Thus, dDA1 lacks the 
BBAXB (B = base; A -- acid; X = any residue) motif at the 
carboxyl-end of the third cytoplasmic loop which is conserved 
in all Dl-like receptors and has been implicated as one of the 
regions regulating Gs protein activation. Interestingly enough, 
this sequence motif may be inverted in dDA1 (BXXABB). 
Other putative G protein-activating motifs, BBXB, [41] are, 
however, present in both the amino (KHVK) and middle 
(RRPK; KKFK) portions of this loop. In addition to the third 
cytoplasmic loop, sequences within the carboxyl-tail have been 
shown to determine G protein specificity [42]. In any event, the 
lack of a high degree of amino acid correspondence suggests 
that dDAI is evolutionarily so far removed from its vertebrate 
counterparts hat it can not be reliably classified as a member 
of the DI subfamily of receptors based on structure alone. 
Table 1 
Lack of detectable specific receptor binding activity in COS-7 and Sf9 cell membranes xpressing the dDA 1 receptor 
Labeled compound Receptor selectivity Displacer 
COS-7 cells 
[3H]SCH-23390 
[3H]Spiperone 
[3H]0~-Flupenthixol 
[3H]DHA 
[3H]Prazosin 
[3H]Yohimbine 
[3H]LSD 
[3H]5-HT 
[3H]8-OH-DPAT 
(5.0 nM) Dopamine D1 receptors 100 ¢tM DA 
10/tM SKF-82526 
10 #M (+)-butaclamol 
10 #M ~-flupenthixol 
5 gM SCH-23390 
(2.3 nM) Dopamine D2 receptors 10 ¢tM (+)-butaclamol 
(3.6 nM) Dopamine D1 receptors 5 ¢tM SCH-23390 
(5.0 nM) fl-Adrenergic receptors 10/tM propranolol 
(6.2 nM) ct-Adrenergic receptors 1 ¢tM prazosin 
(4.8 nM) c~-Adrenergic re eptors 10 #M WB-4101 
(2.4 nM) Non-selective 5-HT 10 #M methiothepin 
(5.0 nM) 5-HTl receptors 100/IM 5-HT 
(5.5 nM) 5-HTIA receptor 100 #M 5-HT 
Sf9 cells 
[3H]SCH-23390 (3.3 nM) Dopamine D1 receptors 50 gM 0~-flupenthixol 
100 gM NE, 
100/tM tryptamine 
[3H]Spiperone (1.8 nM) Dopamine D2 receptors 100/tM tryptamine 
[3H]Raclopride (4.8 nM) Dopamine D2 receptors 100 ruM tryptamine 
[3H]YM-09151-2 (1.6 nM) Dopamine D2 receptors 100/IM tryptamine 
[3H]Tryptamine (9.4 nM) 100 gM tryptamine 
[3H]Prazosin (6.6 nM) 0~-Adrenergic re eptors 100/.tM DA/NE/5-HT 
[3H]Yohimbine (12.1 nM) ct-Adrenergic receptors 100 ,uM DA/NE/5-HT 
[3H]DHA (1.0 nM) fl-Adrenergic receptors 100/.tM DA/NE/5-HT 
[3H]WB-4101 (12.0 nM) ~-Adrenergic/5-HT1A receptors 100/IM DA/NE/5-HT 
[3H]LSD (2.3 nM) Non-selective 5-HT 100/IM DA/NE/5-HT 
COS-7 or SI x) membranes xpressing dDA1 receptors were prepared and assayed for radioligand binding to distinct receptor subtypes as described 
in section 2. No specific binding activity, relative to mock infected cells, was noted under any of the conditions listed. Specific activities (1 Ci = 37 
Gbq): [3H]SCH-23390 (NEN, 85.5 Ci/mmol), [3H]spiperone (NEN, 24 Ci/mmol), [3H]c~-flupenthixol (NEN, 14.1 Ci/mmol), [3H]YM-09151-2 (NEN, 
81.4 Ci/mmol), [3H]raclopride (NEN, 77.0 Ci/mmol), [3H]prazosin (NEN, 82.0 Ci/mmol), [3H]yohimbine (NEN, 70.5 Ci/mmol), [3H]DHA (NEN, 105.5 
Ci/mmol), [3H]5HT (NEN, 23.7 Ci/mmol), [3H]8-OH-DPAT (NEN, 163.0 Ci/mmol), [3H]LSD (NEN, 65.2 Ci/mmol), [3H]tryptamine (NEN, 21.2 
Ci/mmol). 
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Fig. 2. Pharmacological specificity of cAMP accumulation i  Sf9 cells 
expressing the dDA1 receptor. (A) Agonist dose-response curves for 
dDA l-mediated cAMP accumulation. I fected Sf9 cells were incubated 
with increasing concentrations of the indicated agonist, and the amount 
of cAMP measured as described in section 2. Estimated ECs0 values 
were determined by KALEIDAGRAPH and are representative of two 
independent experiments conducted induplicated and which varied by 
less than 15%. (B) Bar graph depicting levels of cAMP accumulation 
produced by various dopaminergic agonists (10 pM) compared to basal 
levels and 10 pM DA. 
In order to accurately determine the pharmacological iden- 
tity of dDA 1 we assessed the ability of a number of radiolabeled 
compounds to detect receptor activity on membranes prepared 
from COS-7 cells transiently expressing the dDAI receptor. As 
listed in Table 1, no specific binding was obtained with tritiated 
ligands commonly used to define dopamine D 1-, D2-1ike recep- 
tors, fl- and ~-adrenergic receptors or 5-HT receptors. Most 
significantly, the benzazepine SCH-23390 which binds to D1- 
like receptors with high affinity did not bind to the expressed 
dDA1 receptor. Similarly, using a baculovirus expression sys- 
tem which allows for the high expression of proteins, no specific 
binding was obtained on membranes prepared from Sf9 cells 
infected with the dDAI receptor. The lack of dDA1 binding 
with conventional ligands, which normally act as selective, high 
affinity antagonists atmammalian or vertebrate D l-like recep- 
tors is not surprising. The Drosophila 5HTI, 5HT2A, and 
5HT2B [20-23] and Lymnaea 5HTlym [43] receptors, in partic- 
ular, display pharmacological profiles distinct from their verte- 
brate counterparts and are insensitive to commonly used tritri- 
ated ligands used for serotonin receptor identification. These 
data, when taken together, suggests that the acquisition of these 
binding sites, particularly that for antagonists, appeared to 
have developed some time after the divergence of invertebrates 
and vertebrates. 
Since dopamine-stimulated cAMP production has been ob- 
served in invertebrates, including cockroach, locust, molluscs 
and planaria [17-19,44] we assessed the ability of dDA1 to 
stimulate the formation of cAMP in both COS-7 and Sf9 cells. 
In COS-7 cells transiently expressing dDAI, 10/IM DA, 100 
pM SKF-82526, 100 BM NPA, and 50 pM apomorphine stim- 
ulated the production of cAME albeit to varying levels (3-5 
fold). The dDA1 receptor was also tested for its ability to 
stimulate adenylyl cyclase in Sf9 cells. This system may in fact 
be more appropriate for the assessment of dDAl-mediated 
functional responsivity since the complement ofG proteins and 
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Fig. 3. Pharmacological specificity of the inhibition of DA-stimulated 
cAMP accumulation is Sf9 cells expressing dDA1 receptor. (A) Inhibi- 
tion of DA-stimulated accumulation f cAMP by dopaminergic antag- 
onists. Infected Sf9 cells were pretreated for 15 min with increasing 
concentrations of the indicated antagonists followed by addition of 500 
nM DA (Af~ for an additional 15 rain incubation period. Estimated ICs0 
and K b values were determined by KALEIDAGRAPH and a modified 
Cheung-Prussoff equation [K b = ICs0,/([Ar]/ECs0,) - 1], respectively, 
where Af represents he fixed concentration f dopamine used as de- 
scribed [45]. Data shown are representative of at least wo independent 
experiments each conducted induplicate and which varied by less than 
15%. (B) Bar graph illustrating the ability of various antagonists (1 pM) 
to inhibit levels of cAMP accumulation generated by the addition of 
500 nM DA. 
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A 
Fig. 4. In situ localization of dDA1 receptor mRNA to Drosophila embryos. Figure depicts developmental labeling pattern of dDA1 receptor mRNA 
during (A) syncitial stage mbryo, (B) cellular blastoderm stage mbryo, and (C) germ band extension stage mbryos. Anterior is to the left, posterior 
is to the right. A random primed igoxygenin-dUTP 350 bp XbaI-EcoRI fragment representing primarily the 3' untranslated region of dDA1 cDNA 
was used as a probe with collection and processing of embryos for in situ hybridization as described in section 2. 
adenylyl cylase enzymes present in St9 cells may be more repre- 
sentative of what is constitutive in native neural Drosophila 
cells. In fact, there was an enhanced stimulation of adenylyl 
cyclase activity by dopamine (~ 10 fold), as determined by the 
increased levels of cAMP accumulation, relative to that seen 
with COS-7 cells (data not shown). As depicted in Fig. 2A, 
dopamine and ADTN stimulated, in a concentration-depend- 
ent manner, the production of cAMP in dDA l-infected Sf9 cells 
with high affinity (ECso 300-500 nM, respectively) relative to 
NE (ECs0-7000 nM) and 5-HT (> 1 mM); a pharmacological 
profile clearly indicative of a dopamine receptor. As illustrated 
in Fig. 2B, other dopaminergic agonists or D I selective agonists 
(e.g. SKF-82526, NPA, apomorphine, pergolide and L-dopa) 
also stimulated the production of cAMP, albeit o levels consid- 
erable lower than the agonists mentioned above (2-5 fold over 
basal) with estimated ECs0 values of 10/aM or higher. Whether 
these compounds act as low affinity partial agonists at the 
dDA1 receptor is at present unknown. There was no en- 
dogenous timulation of cAMP production by these agonists 
as determined in mock-transfected Sf9 cells tested in parallel 
(data not shown). The selective dopamine D2-1ike receptor 
agonist LY-17555 and non-selective D1 :D2 receptor agent CY- 
208-243 were ineffective (Fig. 2B). Similarly other neurotrans- 
mitters and agents, such as tyramine, octopamine, serotonin, 
tryptamine, N-acetyl DA and isoproterenol (at concentrations 
of up to 10pM each) were ineffective in stimulating the produc- 
tion of cAMP (data not shown). 
As illustrated in Fig. 3A, the pharmacological profile of clas- 
sically defined dopamine receptor antagonists at inhibiting 
dDAl-mediated stimulation of cAMP in Sf9 cells is distinct 
from that of the vertebrate Dl-like receptor family. Thus, 
dopamine (500 nM)-mediated dDA1 stimulation of cAMP was 
inhibited in a competitive and concentration-dependent man- 
ner by a number of dopamine receptor antagonists with the 
following rank order of potency: butaclamol >SCH- 
23390 > flupenthixol > spiperone and with estimated Kb values 
[45] from -10-100 fold greater than that seen for cloned verte- 
brate D l-like receptors. The poor affinity displayed by the 
selective D 1 receptor antagonist of the benzazepine class, SCH- 
23390 (K b -230 nM), for dDAl-stimulated cAMP is consistent 
with the notion that, as opposed to vertebrates, invertebrate 
dopamine receptors are insensitive to this class of molecule 
(also see above). Other dopamine receptor antagonists, but not 
flAR antagonists, inhibited dDAl-stimulated adenylyl cyclase 
activity in Sf9 cells, albeit with estimated 1C50 values -> 1 /aM 
(Fig. 3B). 
The rank order of potency for neurotransmitter agonists in 
stimulating cAMP production (DA > NE > 5-HT) and the lack 
of stimulation by other possible transmitters (octopamine, tyr- 
amine, tryptamine) and DA metabolites (N-acetyl DA) suggests 
that this receptor operationally may be defined as a dopamine 
Dl-like receptor. The low homology displayed by dDA1 to 
vertebrate dopamine D1 receptors and the presence of introns 
suggests that this receptor may be a progenitor of the dopamine 
D1 receptor subfamily. The fact that selective D1 receptor 
antagonists (thiothixenes, benzazepines) are relatively poor in- 
hibitors of DA-stimulated cAMP production lends support o 
the observed presence of a low affinity benzazepine dopamine 
D l-like receptor stimulating adenylyl cyclase activity in verte- 
brate species [46]. If so, the dDA1 receptor may be a useful 
probe with which to screen for such a gene in vertebrates. 
Indeed, Southern blot analysis of digested Gallus domesticus 
DNA depicts one distinct ~700 bp dDA 1 hydrizing band which 
is not similarly identified by chicken D1A, D1B and DID 
receptor probes (data not shown). Whether this DNA fragment 
represents a novel dopamine Dl-like receptor or another cat- 
echolaminergic receptor gene is currently under investigation. 
Drosophila is an ideal developmental and genetic model that 
may be used to study the effects of this receptor on the develop- 
ing nervous ystem. Dopaminergic cell clusters appear as early 
as 18-20 h of Drosophila embryonic development [24], and 
vertebrate dopamine D l-like receptors have been shown to 
modulate neuronal growth and morphogenesis [4749]. The 
spatial and temporal pattern of dDA1 receptor mRNA expres- 
sion during Drosophila development was assessed by in situ 
hybridization to fly embryos with probes encoding 3' dDA1 
receptor untranslated regions, dDA1 appears to be expressed 
as a maternal transcript since abundant hybridization is ob- 
served at early, syncitial stages prior to the activation of zygotic 
nuclear transcriptions (Fig. 4A). At these and later cellular 
blastoderm stages (Fig. 4B), hybridization is restricted to apical 
regions of the cortical, peripheral cytoplasm. Similar patterns 
of transcript localization have been observed for several of the 
Drosophila 'pair rule' genes which direct embryonic pattern 
formation [50]. In these cases, and perhaps for dDA1, apical 
localization of transcripts directs apical compartmentalization 
of protein products, thereby restricting lateral protein diffusion 
and allowing for the definition of precise spatial domains. At 
later stages of development, dDA1 transcripts are specifically 
associated with the extending erm band and excluded from the 
invaginating posterior mesoderm and presumptive head re- 
gions (Fig. 4C). dDA1 transcripts appear to be uniformly ex- 
pressed in all developing tissues at all subsequent stages of 
embryogenesis (data not shown). Despite these 
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mRNA localization patterns it is still unclear whether dopa- 
mine Dl-l ike receptors affect neuronal differentiation i either 
Drosophila or vertebrates. While still in early stages of charac- 
terization, mice deficient in the D1A receptor gene appear to 
display normal patterns of neuronal circuitry [51]. A recent 
report, however, has described the genomic organization of the 
dDA1 receptor gene and assigned its localization to the region 
of chromosome 35 E-F, an area containing a number of 
mapped lethal mutations (see [52] and refs. therein). It may 
therefore be important to analyze these mutants in order to gain 
a better understanding of the regulation of Dl-l ike receptor 
gene expression and function during Drosophila nervous ystem 
development. 
In summary, the cloning of a possible primordial dopamine 
D l-like receptor stimulating adenylyl cyclase activity in Droso- 
phila may hopefully aid in the identification of those sequence- 
specific motifs that determine subtype specific D1 receptor G 
protein coupling and pharmacological ctivation. Moreover, 
by the creation of inter-species receptor chimeras, the molecu- 
lar substrate underlying high affinity benzazepine r ceptor in- 
teractions, which so typifies vertebrate dopamine D 1 receptors, 
may be localized to a defined region or regions of the receptor. 
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